• Tempest Therapeutics posted a wider net loss of USD 27.7 million for quarter ended March 31, 2026, up 155% from a year earlier as operating loss widened to USD 27.72 million, up 153%.
• Acquired in-process R&D expense rose to USD 22.18 million, while general and administrative costs increased 64% to USD 5.43 million.
• R&D expense dropped 99% to USD 114,000 due to re-prioritizing efforts toward exploring strategic alternatives initiated in April 2025 and culminating in the February 2026 asset acquisition.
• Cash and cash equivalents fell to USD 1.8 million as of March 31, 2026, down from USD 7.7 million at Dec. 31, 2025, with management flagging substantial doubt about going-concern status within 12 months.
• Pipeline update highlighted TPST-2003 interim Phase 1 data showing a 100% complete response rate in 15 CAR-T-naïve efficacy-evaluable patients across REDEEM-1 and POEMS-1, supporting plans to seek an FDA meeting on a potential U.S. registrational study later in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-224289), on May 14, 2026, and is solely responsible for the information contained therein.